Change search
Refine search result
1 - 7 of 7
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Chalmers, J. R.
    et al.
    Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England..
    Simpson, E.
    Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA..
    Apfelbacher, C. J.
    Univ Regensburg, Inst Epidemiol & Prevent Med, Med Sociol, D-93053 Regensburg, Germany..
    Thomas, K. S.
    Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England..
    von Kobyletzki, Laura B.
    Karlstad University, Faculty of Health, Science and Technology (starting 2013), Department of Health Sciences (from 2013). Lund Univ, Skane Univ Hospital, Dept Dermatol, Malmo, Sweden.
    Schmitt, J.
    Univ Dresden, Ctr Lvidence Based Hlthcare, Dresden, Germany.;Tech Univ Dresden, Dept Occupat & Social Med, D-01062 Dresden, Germany..
    Singh, J. A.
    Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.;Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA..
    Svensson, A.
    Malmo Univ Hosp, Dept Dermatol & Venerol, Malmo, Sweden..
    Williams, H. C.
    Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England..
    Abuabara, K.
    Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA..
    Aoki, V.
    Univ Sao Paulo, Sch Med, Dept Dermatol, Sao Paulo, Brazil..
    Ardeleanu, M.
    Regeneron Pharmaceut Inc, Immunol & Inflammat, New York, NY USA..
    Awici-Rasmussen, M.
    Psoriasis & Eczema Assoc Norway, Oslo, Norway..
    Barbarot, S.
    CHU Nantes, Dept Dermatol, F-44035 Nantes 01, France..
    Berents, T. L.
    Univ Oslo, Inst Clin Med, Oslo 3, Norway.;Oslo Univ Hosp, Dept Dermatol, Oslo, Norway..
    Block, J.
    Natl Eczema Assoc, Natl Eczema Org, San Rafael, CA USA..
    Bragg, A.
    Chugai Pharma Europe Ltd, London, England..
    Burton, T.
    Clemmensen, K. K. Bjerring
    Univ Copenhagen, Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark..
    Creswell-Melville, A.
    Soc Canadienne IEczema, Keswick, ON, Canada..
    Dinesen, M.
    LEO Pharma AS, Industriparken 55, Ballerup, Denmark..
    Drucker, A.
    Univ Hlth Nem ork, Div Dermatol, Toronto, ON, Canada..
    Eckert, L.
    Hlth Econ & Outcomes Res, Sanofi, France..
    Flohr, C.
    Guys & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, London, England.;Kings Coll London, London, England..
    Garg, M.
    LEO Pharma, Copenhagen, Denmark..
    Gerbens, L. A. A.
    Univ Amsterdam, Acad Med Ctr, Dept Dermatol, Amsterdam, Netherlands..
    Graff, A. L. B.
    Natl Eczema Soc, London, England..
    Hanifin, J.
    Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA..
    Heinl, D.
    Univ Regensburg, Inst Epidemiol & Prevent Med, Med Sociol, D-93053 Regensburg, Germany..
    Humphreys, R.
    Natl Eczema Soc, London, England..
    Ishii, H. A.
    Brazilian Atop Dermatitis Assoc AADA, Sao Paulo, Brazil..
    Kataoka, Y.
    Osaka Prefectural Med Ctr Resp & Allerg Dis, Osaka, Japan..
    Leshem, Y. A.
    Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA..
    Marquort, B.
    Massuel, M. -A
    Merhand, S.
    Assoc Francaise Eczema, Redon, France..
    Mizutani, H.
    Mie Univ, Grad Sch Med, Tsu, Mie, Japan.;Mie Univ, Hosp Tsu, Tsu, Mie, Japan..
    Murota, H.
    Osaka Univ, Dept Dermatol, Osaka, Japan..
    Murrell, D. F.
    St George Hosp, Dept Dermatol, Sydney, NSW, Australia.;Univ New S Wales, Sydney, NSW, Australia..
    Nakahara, T.
    Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Japan..
    Nasr, I.
    Nograles, K.
    Greater New York City Area Pharmaceut, Celgene Corp, New York, NY USA..
    Ohya, Y.
    Natl Ctr Child Hlth & Dev, Dept Med Subspecialties, Div Allergy, Tokyo, Japan..
    Osterloh, I.
    Ostermed Ltd, Kent, OH USA..
    Pander, J.
    Celgene BV, Utrecht, Netherlands..
    Prinsen, C.
    Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Dept Epidemiol & Biostat, Amsterdam, Netherlands..
    Purkins, L.
    Ziarco Pharma Ltd, Canterbury, Kent, England..
    Ridd, M.
    Univ Bristol, Sch Social & Community Med, Bristol, Avon, England..
    Sach, T.
    Univ E Anglia, Hlth Econ Grp, Norwich, Norfolk, England..
    Schuttelaar, M. -LA.
    Shindo, S.
    Osaka Univ, Dept Dermatol, Osaka, Japan..
    Smirnova, J.
    Karlstad Univ, Dept Publ Hlth Sci, Karlstad, Sweden..
    Sulzer, A.
    Sanofi Aventis, Montpellier, France..
    Gjerde, E. Synnove
    Psoriasis & Eczema Assoc Norway, Oslo, Norway..
    Takaoka, R.
    Univ Sao Paulo, Sch Med, Dept Dermatol, Sao Paulo, Brazil..
    Talmo, H. Vestby
    Sanofi Aventis, Montpellier, France..
    Tauber, M.
    Toulouse Univ, Toulouse, France..
    Torchet, F.
    Mie Univ, Grad Sch Med, Tsu, Mie, Japan.;Mie Univ, Hosp Tsu, Tsu, Mie, Japan..
    Volke, A.
    Univ Tartu, Dept Dermatol, Tartu, Estonia..
    Wahlgren, C. -F
    Weidinger, S.
    Venereol & Allergy Univ Hosp Schleswig Holstein, Dept Dermatol, Kiel, Germany..
    Weisshaar, E.
    Heidelberg Univ, Dept Social Med, Occupat & Environm Dermatol, Heidelberg, Germany..
    Wollenberg, A.
    Univ Munich, Dept Dermatol & Allergy, Munich, Germany..
    Yamaga, K.
    Osaka Univ, Dept Dermatol, Osaka, Japan..
    Zhao, C. Y.
    St George Hosp, Dept Dermatol, Sydney, NSW, Australia.;Univ New S Wales, Sydney, NSW, Australia..
    Spuls, P. I.
    Univ Amsterdam, Acad Med Ctr, Dept Dermatol, Amsterdam, Netherlands..
    Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)2016In: British Journal of Dermatology, ISSN 0007-0963, E-ISSN 1365-2133, Vol. 175, no 1, p. 69-79Article in journal (Refereed)
    Abstract [en]

    This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmo, Sweden on 23-24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [ including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms.

  • 2. Chalmers, J. R.
    et al.
    Thomas, K. S.
    Apfelbacher, C.
    Williams, H. C.
    Prinsen, C. A.
    Spuls, P. I.
    Simpson, E.
    Gerbens, L. A. A.
    Boers, M.
    Barbarot, S.
    Stalder, J. F.
    Abuabara, K.
    Aoki, V.
    Ardeleanu, M.
    Armstrong, J.
    Bang, B.
    Berents, T. L.
    Burton, T.
    Butler, L.
    Chubachi, T.
    Cresswell-Melville, A.
    DeLozier, A.
    Eckert, L.
    Eichenfield, L.
    Flohr, C.
    Futamura, M.
    Gadkari, A.
    Gjerde, E. S.
    van Halewijn, K. F.
    Hawkes, C.
    Howells, L.
    Howie, L.
    Humphreys, R.
    Ishii, H. A.
    Kataoka, Y.
    Katayama, I.
    Kouwenhoven, W.
    Langan, S. M.
    Leshem, Y. A.
    Merhand, S.
    Mina-Osorio, P.
    Murota, H.
    Nakahara, T.
    Nunes, F. P.
    Nygaard, U.
    Nygardas, M.
    Ohya, Y.
    Ono, E.
    Rehbinder, E.
    Rogers, N. K.
    Romeijn, G. L. E.
    Schuttelaar, M. L. A.
    Sears, A. V.
    Simpson, M. A.
    Singh, J. A.
    Srour, J.
    Stuart, B.
    Svensson, A.
    Talmo, G.
    Talmo, H.
    Teixeira, H. D.
    Thyssen, J. P.
    Todd, G.
    Torchet, F.
    Volke, A.
    von Kobyletzki, Laura B.
    Karlstad University, Faculty of Health, Science and Technology (starting 2013), Department of Health Sciences (from 2013). Karolinska Institutet; Lund University; University Hospital Schleswig-Holstein, Kiel, Germany.
    Weisshaar, E.
    Wollenberg, A.
    Zaniboni, M.
    Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)2018In: British Journal of Dermatology, ISSN 0007-0963, E-ISSN 1365-2133, Vol. 178, no 5, p. E332-E341Article in journal (Refereed)
    Abstract [en]

    This is the report from the fifth meeting of the Harmonising Outcome Measures for Eczema initiative (HOME V). The meeting was held on 12-14 June 2017 in Nantes, France, with 81 participants. The main aims of the meeting were (i) to achieve consensus over the definition of the core domain of long-term control and how to measure it and (ii) to prioritize future areas of research for the measurement of the core domain of quality of life (QoL) in children. Moderated whole-group and small-group consensus discussions were informed by presentations of qualitative studies, systematic reviews and validation studies. Small-group allocations were performed a priori to ensure that each group included different stakeholders from a variety of geographical regions. Anonymous whole-group voting was carried out using handheld electronic voting pads according to pre-defined consensus rules. It was agreed by consensus that the long-term control domain should include signs, symptoms, quality of life and a patient global instrument. The group agreed that itch intensity should be measured when assessing long-term control of eczema in addition to the frequency of itch captured by the symptoms domain. There was no recommendation of an instrument for the core outcome domain of quality of life in children, but existing instruments were assessed for face validity and feasibility, and future work that will facilitate the recommendation of an instrument was agreed upon.

  • 3.
    Howells, L.
    et al.
    Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England.
    von Kobyletzki, Laura B.
    Lunds universitet.
    Beckman, Linda
    Karlstad University, Faculty of Health, Science and Technology (starting 2013), Department of Health Sciences (from 2013).
    Defining and measuring 'eczema control': an international qualitative study to explore the views of those living with and treating atopic eczema2019In: Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, E-ISSN 1468-3083, Vol. 33, no 6, p. 1124-1132Article in journal (Refereed)
    Abstract [en]

    Background Atopic eczema (also known as eczema) is a chronic, inflammatory skin condition that often afflicts patients' health and well-being. The Harmonising Outcome Measures for Eczema (HOME) initiative recommends that 'long-term control of eczema' is measured in all clinical trials 3 months or longer in duration. However, little has been published on what eczema control means to those living with or treating atopic eczema. Objectives To (i) develop understanding of what eczema control means to patients, carers and clinicians and (ii) explore the feasibility and acceptability of different ways of measuring eczema control in the long term. Methods Online focus groups explored patients/carers experiences in the UK, the United States, the Netherlands, France, Sweden and Japan, and an international online survey gathered views of clinicians. The framework method was used to analyse the focus groups, and thematic analysis was used to analyse survey data. All findings were integrated into a theoretical framework to create overarching themes that cut across these diverse groups. Results Eight focus groups with patients (16 years+) and eight groups with carers of children took place (N = 97). Sixty-two people took part in the survey. Eczema control was described as a multifaceted construct involving changes in disease activity, the treatment and management of the condition and psychological, social and physical functioning. Patient/carer measurement allows personal accounts and frequent measurement, whilst clinician measurement was deemed less subjective. The burden on patients/carers and issues for analysing and interpreting data should be considered. Conclusions This study formed the basis of judging the content validity and feasibility of measurement instruments/methods to assess control of eczema in clinical trials. This online approach to an international qualitative study is an example of how core outcome set developers with limited resources can engage with multiple stakeholder groups on an international basis to inform consensus meeting discussions.

  • 4.
    Mørk, Cato
    et al.
    Department of Dermatology, Rikshospitalet University Hospital, Norway.
    Salerud, E Göran
    Department of Biomedical Engineering, Linköping University.
    Asker, Claes L
    Karlstad University, Division for Chemistry.
    Kvernebo, Knut
    Department of Cardiothoracic Surgery, Ullevaal University Hospital, Norway.
    The Prostaglandin E1 Analog Misoprostol Reduces Symptoms and Microvascular Arteriovenous Shunting in Erythromelalgia: A Double-Blind, Crossover, Placebo-Compared Study2004In: Journal of Investigative Dermatology, ISSN 0022-202X, E-ISSN 1523-1747, Vol. 122, no 3, p. 587-593Article in journal (Refereed)
    Abstract [en]

    Based on previous experience with parenteral prostanoids, we studied the effect of misoprostol treatment, an orally administered prostaglandin E1 analog, in patients with erythromelalgia. Treatment with placebo was followed by treatment with misoprostol (0.4–0.8 mg per d), both for 6 wk. The patients (n=21) and a study nurse who administered the trial were blinded. The endpoints were change in pain and need for cooling and global assessment of the treatment. Following central body heat provocation, global skin perfusion, capillary morphology, and change in pain were also recorded before and after each treatment period. Results were compared with data from healthy control subjects (n=11) that did not undergo treatment. Clinical safety and tolerability evaluation included physical examinations, clinical laboratory tests, and monitoring of adverse events. All clinical outcome measures were significantly better after treatment with misoprostol (p<0.01) as compared with placebo treatment and after a 3-mo follow-up without treatment. The heat-induced increase in global perfusion after misoprostol treatment was similar to the control group and significantly lower when compared with baseline (p<0.01) and placebo treatment (p<0.05), respectively. This study demonstrates that misoprostol is clinically superior to placebo in patients with erythromelalgia. The results of the perfusion studies may imply that the mechanism of action of the beneficial effect of misoprostol is reduced microvascular arteriovenous shunting in affected skin.

  • 5.
    von Kobyletzki, Laura B.
    Karlstad University, Faculty of Health, Science and Technology (starting 2013), Department of Health Sciences (from 2013). Lund Univ, Skne Univ Hosp, Dept Dermatol, Inst Clin Res Malmo, Malmo, Sweden.;Karlstad Univ, Dept Publ Hlth Sci, Karlstad, Sweden..
    Atopic eczema and nonatopic eczema show the same pattern in an adolescent general population2015In: British Journal of Dermatology, ISSN 0007-0963, E-ISSN 1365-2133, Vol. 173, no 4, p. 889-889Article in journal (Refereed)
  • 6.
    von Kobyletzki, Laura B
    et al.
    Karlstad University, Faculty of Health, Science and Technology (starting 2013), Department of Health Sciences. Lund Univ, Skne Univ Hosp, Dept Dermatol, Inst Clin Res Malmo, Malmo, Sweden.;Karlstad Univ, Dept Publ Hlth Sci, Karlstad, Sweden..
    Mischo, M.
    Ruhr Univ Bochum, Bochum, Germany..
    Schmidt, D. A.
    N Carolina Agr & Tech State Univ, Dept Phys, Greensboro, NC 27411 USA..
    Bruendermann, E.
    Ruhr Univ Bochum, Bochum, Germany..
    Brockmeyer, N. H.
    Ruhr Univ Bochum, Dept Dermatol, Bochum, Germany..
    Potthoff, A.
    Ruhr Univ Bochum, Dept Dermatol, Bochum, Germany..
    Havenith, M.
    Ruhr Univ Bochum, Bochum, Germany..
    Changes in Antioxidant and Lipid Network in HIV patients compared to young and old patients: Probing Epidermis and Dermis by Raman Spectroscopy2012In: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, E-ISSN 1610-0387, Vol. 10, p. 15-15Article in journal (Refereed)
  • 7.
    von Kobyletzki, Laura B
    et al.
    Karlstad University, Faculty of Health, Science and Technology (starting 2013), Department of Health Sciences. Lund Univ, Skne Univ Hosp, Dept Dermatol, Inst Clin Res Malmo, Malmo, Sweden.;Karlstad Univ, Dept Publ Hlth Sci, Karlstad, Sweden..
    Mischo, Meike
    Schmidt, Diedrich A.
    N Carolina Agr & Tech State Univ, Dept Phys, Greensboro, NC USA..
    Brundermann, Erik
    Brockmeyer, Norbert H.
    Ruhr Univ Bochum, Dept Dermatol, Bochum, Germany..
    Potthoff, Anja
    Ruhr Univ Bochum, Dept Dermatol, Bochum, Germany..
    Havenith, Martina
    Probing epidermis and dermis by Raman spectroscopy: changes in antioxidant and lipid network with age and disease2012In: International Journal of Cosmetic Science, ISSN 0142-5463, E-ISSN 1468-2494, Vol. 34, no 4, p. 372-373Article in journal (Refereed)
1 - 7 of 7
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf